novel medicines for patients with hormone driven cancers
Hormone receptor positive (HR+) cancers, including, prostate, breast, and ovarian result in >100,000 deaths per year in the United States. Decades old antihormonals and chemotherapies are still the most used therapies to treat these cancers.
Apristor is an investigational medicine for breast, ovarian, and endometrial cancers. These cancers are progesterone-dependent and Apristor functions by blocking the progesterone receptor.